Country data on AMR in Vietnam in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicines and clinical outcome.


Journal

The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617

Informations de publication

Date de publication:
06 09 2022
Historique:
entrez: 6 9 2022
pubmed: 7 9 2022
medline: 9 9 2022
Statut: ppublish

Résumé

Antimicrobial resistance (AMR) is one of the biggest threats to global public health. Selection of resistant bacteria is driven by inappropriate use of antibiotics, amongst other factors. COVID-19 may have exacerbated AMR due to unnecessary antibiotic prescribing. Country-level knowledge is needed to understand options for action. To review the current situation with respect to AMR in Vietnam and initiatives addressing it. Identifying areas where more information is required will provide a call to action to minimize any further rises in AMR within Vietnam and improve patient outcomes. National initiatives to address AMR in Vietnam, antibiotic use and prescribing, and availability of susceptibility data, in particular for the key community-acquired respiratory tract infection (CA-RTI) pathogens Streptococcus pneumoniae and Haemophilus influenzae, were identified. National and international antibiotic prescribing guidelines for CA-RTIs (community-acquired pneumonia, acute otitis media and acute bacterial rhinosinusitis) commonly used locally were also reviewed, plus local antibiotic availability. Insights from clinicians in Vietnam were sought to contextualize this information. In Vietnam there have been some initiatives addressing AMR; Vietnam was the first country in the Western Pacific Region to develop a national action plan to combat AMR, which according to the WHO is being implemented. Vietnam also has one of the highest rates of AMR in Asia due, in part, to the overuse of antimicrobial drugs, both in the animal health sector and in humans in both hospitals and the community. In addition, despite a 2005 law requiring antibiotic prescription, there is unrestricted access to over-the-counter antibiotics. Several global surveillance studies provide antibiotic susceptibility data for CA-RTI pathogens in Vietnam including Survey of Antibiotic Resistance (SOAR) and SENTRY (small isolate numbers only). For management of the common CA-RTIs in Vietnam there are several country-specific local antibiotic prescribing guidelines and in addition, there is a range of international guidelines referred to, but these may have been created based on pathogen resistance patterns that might be very different to those in Vietnam. Expert clinician opinion confirms the high resistance rates among common respiratory pathogens. A more standardized inclusive approach in developing local guidelines, using up-to-date surveillance data of isolates from community-acquired infections in Vietnam, could make management guideline use more locally relevant for clinicians. This would pave the way for a higher level of appropriate antibiotic prescribing and improved adherence. This would, in turn, potentially limit AMR development and improve clinical outcomes for patients.

Sections du résumé

BACKGROUND
Antimicrobial resistance (AMR) is one of the biggest threats to global public health. Selection of resistant bacteria is driven by inappropriate use of antibiotics, amongst other factors. COVID-19 may have exacerbated AMR due to unnecessary antibiotic prescribing. Country-level knowledge is needed to understand options for action.
OBJECTIVES
To review the current situation with respect to AMR in Vietnam and initiatives addressing it. Identifying areas where more information is required will provide a call to action to minimize any further rises in AMR within Vietnam and improve patient outcomes.
METHODS
National initiatives to address AMR in Vietnam, antibiotic use and prescribing, and availability of susceptibility data, in particular for the key community-acquired respiratory tract infection (CA-RTI) pathogens Streptococcus pneumoniae and Haemophilus influenzae, were identified. National and international antibiotic prescribing guidelines for CA-RTIs (community-acquired pneumonia, acute otitis media and acute bacterial rhinosinusitis) commonly used locally were also reviewed, plus local antibiotic availability. Insights from clinicians in Vietnam were sought to contextualize this information.
CONCLUSIONS
In Vietnam there have been some initiatives addressing AMR; Vietnam was the first country in the Western Pacific Region to develop a national action plan to combat AMR, which according to the WHO is being implemented. Vietnam also has one of the highest rates of AMR in Asia due, in part, to the overuse of antimicrobial drugs, both in the animal health sector and in humans in both hospitals and the community. In addition, despite a 2005 law requiring antibiotic prescription, there is unrestricted access to over-the-counter antibiotics. Several global surveillance studies provide antibiotic susceptibility data for CA-RTI pathogens in Vietnam including Survey of Antibiotic Resistance (SOAR) and SENTRY (small isolate numbers only). For management of the common CA-RTIs in Vietnam there are several country-specific local antibiotic prescribing guidelines and in addition, there is a range of international guidelines referred to, but these may have been created based on pathogen resistance patterns that might be very different to those in Vietnam. Expert clinician opinion confirms the high resistance rates among common respiratory pathogens. A more standardized inclusive approach in developing local guidelines, using up-to-date surveillance data of isolates from community-acquired infections in Vietnam, could make management guideline use more locally relevant for clinicians. This would pave the way for a higher level of appropriate antibiotic prescribing and improved adherence. This would, in turn, potentially limit AMR development and improve clinical outcomes for patients.

Identifiants

pubmed: 36065731
pii: 6692270
doi: 10.1093/jac/dkac214
pmc: PMC9445855
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

i26-i34

Subventions

Organisme : GlaxoSmithKline

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.

Références

J Antimicrob Chemother. 2022 Sep 6;77(Supplement_1):i2-i9
pubmed: 36065724
Antimicrob Resist Infect Control. 2020 Jan 14;9(1):16
pubmed: 31956405
Glob Health Med. 2019 Dec 31;1(2):61-64
pubmed: 33330756
Pharmacoepidemiol Drug Saf. 2015 Feb;24(2):129-36
pubmed: 24648269
J Antimicrob Chemother. 2020 Oct 1;75(10):2902-2906
pubmed: 32728698
Acta Paediatr. 2021 Jun;110(6):1916-1923
pubmed: 33544434
Bull World Health Organ. 2018 Feb 1;96(2):135-137
pubmed: 29403117
Pneumonia (Nathan). 2017 Apr 25;9:7
pubmed: 28702309
J Antimicrob Chemother. 2020 Apr 1;75(Suppl 1):i19-i42
pubmed: 32337597
Clin Microbiol Infect. 2004 Apr;10 Suppl 2:18-27
pubmed: 14759230
J Antimicrob Chemother. 2016 May;71 Suppl 1:i85-91
pubmed: 27048585
J Antimicrob Chemother. 2016 May;71 Suppl 1:i93-102
pubmed: 27048586
N Engl J Med. 2015 Jul 30;373(5):415-27
pubmed: 26172429
JAC Antimicrob Resist. 2020 Sep;2(3):dlaa048
pubmed: 32974610
Rhinology. 2020 Feb 20;58(Suppl S29):1-464
pubmed: 32077450
Arch Dis Child. 2020 Aug;105(8):713-719
pubmed: 32079569
Paediatr Respir Rev. 2021 Sep;39:65-70
pubmed: 33158773
Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72
pubmed: 17278083
Euro Surveill. 2015 May 28;20(21):
pubmed: 26062562
J Antimicrob Chemother. 2002 Jan;49(1):31-40
pubmed: 11751764
J Glob Antimicrob Resist. 2019 Sep;18:269-278
pubmed: 31201995
BMC Public Health. 2019 Nov 26;19(1):1560
pubmed: 31771536
PLoS One. 2020 Oct 20;15(10):e0240830
pubmed: 33079967
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3463-E3470
pubmed: 29581252
Clin Microbiol Rev. 2007 Jul;20(3):391-408, table of contents
pubmed: 17630331
Trans R Soc Trop Med Hyg. 2011 Nov;105(11):628-36
pubmed: 21962293
Thorax. 2012 Jan;67(1):71-9
pubmed: 20729232
BMJ Glob Health. 2021 Jul;6(7):
pubmed: 34257138
Clin Infect Dis. 2012 Apr;54(8):e72-e112
pubmed: 22438350
Thorax. 2011 Oct;66 Suppl 2:ii1-23
pubmed: 21903691
Clin Microbiol Infect. 2019 Jul;25(7):910-911
pubmed: 30910717
Pediatrics. 2013 Mar;131(3):e964-99
pubmed: 23439909
BMC Public Health. 2020 Feb 11;20(1):213
pubmed: 32046713
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
Antimicrob Resist Infect Control. 2021 May 10;10(1):78
pubmed: 33971969
Thorax. 2009 Oct;64 Suppl 3:iii1-55
pubmed: 19783532
Clin Infect Dis. 2011 Oct;53(7):e25-76
pubmed: 21880587
BMC Pharmacol Toxicol. 2014 Feb 20;15:6
pubmed: 24555709

Auteurs

Didem Torumkuney (D)

GlaxoSmithKline, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.

Subhashri Kundu (S)

GlaxoSmithKline, 23 Rochester Park, 139234Singapore.

Giap Van Vu (GV)

Respiratory Center, Bach Mai Hospital, Hanoi 100000, Vietnam.

Hoang Anh Nguyen (HA)

The National Centre for Drug Information and Adverse Drug Reactions Monitoring, Hanoi University of Pharmacy, Hanoi, Vietnam.

Hung Van Pham (HV)

University of Medicine and Pharmacy, 217 Hong Bang Street, Ward 11, District 5, Ho Chi Minh City, Vietnam.

Praveen Kamble (P)

GlaxoSmithKline, 252, Dr Annie Besant Road, Worli, 400030 Mumbai, India.

Ngoc Truong Ha Lan (N)

GlaxoSmithKline Vietnam, Unit 701, 235 Dong Khoi, District 1, Ho Chi Minh City, Vietnam.

Nergis Keles (N)

GlaxoSmithKline, Büyükdere Cad. No: 173, 1. Levent Plaza B Blok 34394 Levent, Istanbul, Türkiye.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH